Value of allogeneic stem cell transplantation versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: a prospective randomized European intergroup trial KU Leuven
Background: Allogeneic stem cell transplantation (alloSCT) is usually considered the only curative treatment option for patients with advanced or transformed myelodysplasia (MDS) in complete remission (CR), but postremission chemotherapy and autologous stem cell transplantation are potential alternatives, especially in patients older 45 years. Design and Methods: We evaluated after intensive antileukemic remission-induction chemotherapy the ...